Activity Description
This course brings together four expert optometrists to explore the diagnosis and management of ocular surface disease, including Demodex blepharitis, meibomian gland dysfunction, dry eye disease, and inflammation, while also addressing the recognition and management of antibody-drug conjugate related ocular toxicities in oncology patients.
Accreditation Statements
Sponsored by
Axiom Ophthalmic, LLC is a COPE-Approved Administrator.
This activity, COPE Activity Number 133116, is accredited by COPE for continuing education for optometrists. This course is approved for 1.0 hours of CE.
Course # 104785-TD
Activity # 133116
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Release Date: 7-31-2026
Expiration Date: 07-31-2027
Target Audience
This accredited educational activity is designed for optometrists.
Grant Support Statement
This activity is supported by an unrestricted educational grant from AbbVie, Harrow, Sight Sciences, Sun Pharma, and Tarsus.
Faculty
Marc Bloomenstein, OD, FAAO
- Program Chair
- Schwartz Laser Eye Center
- Phoenix, Arizona
Mile Brujic, OD, FAAO
- Premier Vision Group
- Bowling Green, Ohio
Cecelia Koetting, OD, FAAO, DipABO
- Assistant Professor, Ophthalmology
- University of Colorado School of Medicine
- Aurora, Colorado
Jacob Lang, OD, FAAO
- Associated Eye Care
- Stillwater, Minnesota
Program Description
This course brings together four expert optometrists to explore the diagnosis and management of ocular surface disease, including Demodex blepharitis, meibomian gland dysfunction, dry eye disease, and inflammation, while also addressing the recognition and management of antibody-drug conjugate related ocular toxicities in oncology patients.
Expert Faculty
- Marc Bloomenstein, OD, FAAO
- Mile Brujic, OD, FAAO
- Cecelia Koetting, OD, FAAO, DipABO
- Jacob Lang, OD, FAAO
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Identify and stage patients with eyelid margin disease (meibomian gland dysfunction [MGD] and Demodex Blepharitis [DB]), tear deficiency, and acute and chronic ocular Inflammation by incorporating consistent examination techniques to recognize the pathognomonic signs.
- Assess traditional and emerging diagnostic methods, including tear osmolarity, MMP-9, anterior segment OCT, meibography/gland expression, collarette detection, and incorporate validated symptom questionnaires and objective clinical data to improve the accuracy of OSD/DED diagnosis.
- Evaluate the various treatment options and apply evidence-based selection criteria to customize management strategies for the latest DB pharmaceuticals, neuromodulation therapies, anti-inflammatories (acute and chronic), mechanical and pharmacological MGD treatments.
- Recognize the ocular findings associated with antibody-drug conjugates (ADCs) for the treatment of certain cancers, perform the appropriate baseline and follow-up ophthalmic exams for patients receiving ADC therapy, and develop effective communication strategies with the patient’s shared care team.
Credit Designation
This enduring educational activity is eligible for COPE-accredited continuing education credit.
Credit Hours: 0.5
